EP3298033A4 - Zusammensetzungen und verfahren für tcr-programmierung mit fusionsproteinen - Google Patents

Zusammensetzungen und verfahren für tcr-programmierung mit fusionsproteinen Download PDF

Info

Publication number: EP3298033A4
Authority: EP; European Patent Office
Prior art keywords: compositions; methods; fusion proteins; reprogramming; tcr
Prior art date: 2015-05-18
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

EP16797244.7A

Other languages

English (en)

French (fr)

Other versions

EP3298033B2 (de

EP3298033A1 (de

EP3298033B1 (de

Inventor

Patrick Baeuerle

Gregory Sieczkiewicz

Robert Hofmeister

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

TCR2 Therapeutics Inc

Original Assignee

TCR2 Therapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-05-18

Filing date

2016-05-18

Publication date

2018-10-24

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57320750&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP3298033(A4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2016-05-18 Application filed by TCR2 Therapeutics Inc filed Critical TCR2 Therapeutics Inc

2016-05-18 Priority to EP18207665.3A priority Critical patent/EP3466967A1/de

2016-05-18 Priority to EP20180627.0A priority patent/EP3770168A1/de

2018-03-28 Publication of EP3298033A1 publication Critical patent/EP3298033A1/de

2018-10-24 Publication of EP3298033A4 publication Critical patent/EP3298033A4/de

2020-08-05 Application granted granted Critical

2020-08-05 Publication of EP3298033B1 publication Critical patent/EP3298033B1/de

2023-07-12 Publication of EP3298033B2 publication Critical patent/EP3298033B2/de

Status Active legal-status Critical Current

2036-05-18 Anticipated expiration legal-status Critical

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/32—T-cell receptors [TCR]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/421—Immunoglobulin superfamily
- A61K40/4211—CD19 or B4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/4214—Receptors for cytokines
- A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
Biochemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Zoology (AREA)
Cell Biology (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biotechnology (AREA)
Wood Science & Technology (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)
Hematology (AREA)
Microbiology (AREA)
Pharmacology & Pharmacy (AREA)
General Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Mycology (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

EP16797244.7A 2015-05-18 2016-05-18 Zusammensetzungen und medizinische verwendung für tcr-programmierung mit fusionsproteinen Active EP3298033B2 (de)

Priority Applications (2)

Application Number	Priority Date	Filing Date	Title
EP18207665.3A EP3466967A1 (de)	2015-05-18	2016-05-18	Zusammensetzungen und verfahren für tcr-programmierung mit fusionsproteinen
EP20180627.0A EP3770168A1 (de)	2015-05-18	2016-05-18	Zusammensetzungen und verfahren zur tcr-reprogrammierung mithilfe von fusionsproteinen

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201562163342P	2015-05-18	2015-05-18
PCT/US2016/033146 WO2016187349A1 (en)	2015-05-18	2016-05-18	Compositions and methods for tcr reprogramming using fusion proteins

Related Child Applications (4)

Application Number	Title	Priority Date	Filing Date
EP18207665.3A Division-Into EP3466967A1 (de)	2015-05-18	2016-05-18	Zusammensetzungen und verfahren für tcr-programmierung mit fusionsproteinen
EP18207665.3A Division EP3466967A1 (de)	2015-05-18	2016-05-18	Zusammensetzungen und verfahren für tcr-programmierung mit fusionsproteinen
EP20180627.0A Division-Into EP3770168A1 (de)	2015-05-18	2016-05-18	Zusammensetzungen und verfahren zur tcr-reprogrammierung mithilfe von fusionsproteinen
EP20180627.0A Division EP3770168A1 (de)	2015-05-18	2016-05-18	Zusammensetzungen und verfahren zur tcr-reprogrammierung mithilfe von fusionsproteinen

Publications (4)

Publication Number	Publication Date
EP3298033A1 EP3298033A1 (de)	2018-03-28
EP3298033A4 true EP3298033A4 (de)	2018-10-24
EP3298033B1 EP3298033B1 (de)	2020-08-05
EP3298033B2 EP3298033B2 (de)	2023-07-12

Family

ID=57320750

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
EP16797244.7A Active EP3298033B2 (de)	2015-05-18	2016-05-18	Zusammensetzungen und medizinische verwendung für tcr-programmierung mit fusionsproteinen
EP18207665.3A Withdrawn EP3466967A1 (de)	2015-05-18	2016-05-18	Zusammensetzungen und verfahren für tcr-programmierung mit fusionsproteinen
EP20180627.0A Withdrawn EP3770168A1 (de)	2015-05-18	2016-05-18	Zusammensetzungen und verfahren zur tcr-reprogrammierung mithilfe von fusionsproteinen

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
EP18207665.3A Withdrawn EP3466967A1 (de)	2015-05-18	2016-05-18	Zusammensetzungen und verfahren für tcr-programmierung mit fusionsproteinen
EP20180627.0A Withdrawn EP3770168A1 (de)	2015-05-18	2016-05-18	Zusammensetzungen und verfahren zur tcr-reprogrammierung mithilfe von fusionsproteinen

Country Status (19)

Country	Link
US (7)	US10442849B2 (de)
EP (3)	EP3298033B2 (de)
JP (4)	JP2018515123A (de)
KR (1)	KR20180029201A (de)
CN (2)	CN114634943A (de)
AU (2)	AU2016264323B2 (de)
BR (1)	BR112017024757A2 (de)
DK (1)	DK3298033T4 (de)
EA (2)	EA202090931A3 (de)
ES (1)	ES2819976T5 (de)
FI (1)	FI3298033T4 (de)
HU (1)	HUE051661T2 (de)
IL (2)	IL303905A (de)
MX (1)	MX2017014822A (de)
PL (1)	PL3298033T5 (de)
PT (1)	PT3298033T (de)
SG (1)	SG10201914069SA (de)
WO (1)	WO2016187349A1 (de)
ZA (1)	ZA201708000B (de)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9273283B2 (en) *	2009-10-29	2016-03-01	The Trustees Of Dartmouth College	Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
US10611837B2 (en)	2014-04-10	2020-04-07	Seattle Children's Hospital	Transgene genetic tags and methods of use
PL3298033T5 (pl)	2015-05-18	2023-10-30	TCR2 Therapeutics Inc.	Kompozycje i zastosowania medyczne do reprogramowania TCR z zastosowaniem białek fuzyjnych
US12577289B2 (en)	2015-06-30	2026-03-17	Arizona Board Of Regents On Behalf Of The University Of Arizona	Surrogate co-receptors for t cells and methods of use
US11059880B2 (en) *	2015-06-30	2021-07-13	Arizona Board Of Regents On Behalf Of The University Of Arizona	Redirected cells with MHC chimeric receptors and methods of use in immunotherapy
US10493139B2 (en)	2015-07-24	2019-12-03	Innovative Cellular Therapeutics CO., LTD.	Humanized anti-CD19 antibody and use thereof with chimeric antigen receptor
US11667691B2 (en)	2015-08-07	2023-06-06	Novartis Ag	Treatment of cancer using chimeric CD3 receptor proteins
AU2016306209B2 (en)	2015-08-07	2023-07-06	Seattle Children's Hospital (dba Seattle Children's Research Institute)	Bispecific CAR T-cells for solid tumor targeting
EP3359650A4 (de) *	2015-10-08	2019-03-20	Innovative Cellular Therapeutics Co., Ltd.	Aktivierung und expansion von zellen
MX2018004721A (es)	2015-10-23	2018-07-06	Eureka Therapeutics Inc	Construcciones quimericas anticuerpo/receptor de celulas t y usos de las mismas.
GB201604458D0 (en)	2016-03-16	2016-04-27	Immatics Biotechnologies Gmbh	Peptides and combination of peptides for use in immunotherapy against cancers
EP3433269B1 (de)	2016-03-23	2023-09-27	Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)	Fusionsproteine von pd-1 und 4-1bb
WO2017192536A1 (en)	2016-05-02	2017-11-09	University Of Kansas	Eliminating mhc restriction from the t cell receptor as a strategy for immunotherapy
US10086055B2 (en) *	2016-06-01	2018-10-02	Promab Biotechnologies, Inc.	Adherent cancer cell line expressing a hematological tumor antigen
CA3032498A1 (en) *	2016-08-02	2018-02-08	TCR2 Therapeutics Inc.	Compositions and methods for tcr reprogramming using fusion proteins
EP4596707A3 (de)	2016-09-19	2025-10-08	University of Southern California	Nicht-radioaktive zytotoxizitätstests
AU2017335634A1 (en)	2016-09-27	2019-03-14	Cero Therapeutics, Inc.	Chimeric engulfment receptor molecules
WO2018067993A1 (en)	2016-10-07	2018-04-12	TCR2 Therapeutics Inc.	Compositions and methods for t-cell receptors reprogramming using fusion proteins
JP7291396B2 (ja)	2016-11-22	2023-06-15	ティーシーアール２セラピューティクスインク．	融合タンパク質を用いたｔｃｒの再プログラミングのための組成物及び方法
EP3548055A4 (de) *	2016-12-02	2020-08-19	University of Southern California	Synthetische immunrezeptoren und verfahren zur verwendung davon
JP2020513754A (ja) *	2016-12-21	2020-05-21	ティーシーアール２セラピューティクスインク．	がん治療用に操作されたｔ細胞
CN110248677B (zh) *	2017-01-05	2023-05-16	上海煦顼技术有限公司	人源化抗cd19抗体及其与嵌合抗原受体的用途
CN110582509A (zh) *	2017-01-31	2019-12-17	诺华股份有限公司	使用具有多特异性的嵌合t细胞受体蛋白治疗癌症
WO2018166589A1 (en) *	2017-03-15	2018-09-20	Biontech Cell & Gene Therapies Gmbh	Antigen receptors and uses thereof
JP7538601B2 (ja)	2017-04-26	2024-08-22	ユーリカセラピューティックス，インコーポレイテッド	キメラ活性化受容体及びキメラ刺激受容体を発現する細胞並びにその使用
EP3615574A4 (de)	2017-04-26	2021-02-24	Eureka Therapeutics, Inc.	Spezifisch glypican 3 erkennende konstrukte und deren verwendung
CN118948892A (zh) *	2017-05-01	2024-11-15	朱诺治疗学股份有限公司	细胞疗法与免疫调节化合物的组合
US11166985B2 (en)	2017-05-12	2021-11-09	Crispr Therapeutics Ag	Materials and methods for engineering cells and uses thereof in immuno-oncology
MX2019013514A (es)	2017-05-12	2020-01-20	Crispr Therapeutics Ag	Materiales y metodos para modificar celulas por ingenieria genetica y usos de los mismos en inmunooncologia.
CA3064000A1 (en)	2017-05-24	2018-11-29	Effector Therapeutics, Inc.	Methods and compositions for cellular immunotherapy
LT3428194T (lt)	2017-07-14	2021-12-10	Immatics Biotechnologies Gmbh	Pagerinta dvejopo savitumo polipeptido molekulė
EP4714966A2 (de)	2017-09-26	2026-03-25	Cero Therapeutics Holdings, Inc.	Chimäre engulfment-rezeptormoleküle und verfahren zur verwendung
WO2019067805A1 (en)	2017-09-27	2019-04-04	University Of Southern California	NEW PLATFORMS FOR CO-STIMULATION, NEW CAR DESIGNS AND OTHER IMPROVEMENTS FOR ADOPTIVE CELL THERAPY
PT3703750T (pt)	2017-11-01	2025-01-17	Memorial Sloan Kettering Cancer Center	Recetores de antigénio quimérico específicos para o antigénio de maturação das células b e polinucleótidos codificantes
US11851679B2 (en)	2017-11-01	2023-12-26	Juno Therapeutics, Inc.	Method of assessing activity of recombinant antigen receptors
PT3674328T (pt) *	2018-02-01	2024-03-14	Innovent Biologics Suzhou Co Ltd	Recetor de antigénio quimérico (car) que se liga a bcma e utilizações do mesmo
EP3674327A4 (de) *	2018-02-01	2021-05-05	Nanjing Iaso Biotherapeutics Co., Ltd.	Bindung von chimärem antigen-rezeptor (car) an bcma und verwendungen davon
WO2019157279A1 (en) *	2018-02-10	2019-08-15	Berkeley Lights, Inc.	Mutant idh1 specific t cell receptor
WO2019157454A1 (en)	2018-02-11	2019-08-15	Memorial Sloan-Kettering Cancer Center	Non-hla restricted t cell receptors and uses thereof
AU2019222560B2 (en)	2018-02-17	2025-07-03	Flagship Pioneering Innovations V, Inc.	Compositions and methods for membrane protein delivery
MX2020009371A (es) *	2018-03-09	2021-01-08	Tcr2 Therapeutics Inc	Composiciones y métodos para la reprogramación de tcr mediante el uso de proteínas de fusión.
EP3774906A1 (de)	2018-03-28	2021-02-17	Cero Therapeutics, Inc.	Chimäre tim4-rezeptoren und verwendungen davon
CA3093969A1 (en)	2018-03-28	2019-10-03	Cero Therapeutics, Inc.	Expression vectors for chimeric engulfment receptors, genetically modified host cells, and uses thereof
MX2020010241A (es)	2018-03-28	2020-10-16	Cero Therapeutics Inc	Composiciones de inmunoterapia celular y usos de las mismas.
MX2020012028A (es)	2018-05-11	2021-03-29	Crispr Therapeutics Ag	Metodos y composiciones para tratar el cancer.
JP7599205B2 (ja)	2018-06-01	2024-12-13	アンヘレスセラピューティクスインコーポレイテッド	細胞療法のための多様な抗原結合ドメイン、新規プラットフォームおよびその他の強化
SG11202008731XA (en) *	2018-06-19	2020-10-29	Nanjing Legend Biotech Co Ltd	Engineered cells and uses thereof
AU2019302603A1 (en) *	2018-07-13	2021-01-14	Nanjing Legend Biotech Co., Ltd.	Co-receptor systems for treating infectious diseases
BR112021001338A2 (pt) *	2018-07-26	2021-05-04	TCR2 Therapeutics Inc.	composições e métodos para reprogramação de tcr usando proteínas de fusão específicas para o alvo
CA3117978A1 (en)	2018-11-08	2020-05-14	Juno Therapeutics, Inc.	Methods and combinations for treatment and t cell modulation
CN113631718A (zh)	2018-11-14	2021-11-09	旗舰先锋创新V股份有限公司	用于特定隔室货物递送的组合物和方法
CN109735558B (zh) *	2018-12-12	2022-04-15	中南大学	一种重组car19-il24基因、慢病毒载体、car19-il24-t细胞及应用
US20230192805A1 (en) *	2019-01-14	2023-06-22	Nanjing Legend Biotech Co., Ltd.	Chimeric receptor polypeptides and uses thereof
US20220144916A1 (en) *	2019-02-12	2022-05-12	Board Of Regents, The University Of Texas System	High affinity engineered t-cell receptors targeting cmv infected cells
EP3715368A1 (de)	2019-03-28	2020-09-30	Albert-Ludwigs-Universität Freiburg	Chimäre antigenrezeptoren, für solche rezeptoren codierende vektoren, und deren verwendung zur modifikation von t-zellen
WO2020201527A1 (en)	2019-04-04	2020-10-08	Umc Utrecht Holding B.V.	Modified immune receptor constructs
US20220362295A1 (en) *	2019-04-22	2022-11-17	TCR2 Therapeutics Inc.	Compositions and methods for tcr reprogramming using fusion proteins
MX2021013359A (es)	2019-04-30	2022-01-31	Crispr Therapeutics Ag	Terapia de celulas alogénicas de neoplasias malignas de células b usando células t modificadas genéticamente dirigidas a cd19.
WO2020243158A1 (en) *	2019-05-28	2020-12-03	The University Of Vermont And State Agricultural College	Gamma-delta t cell ligands for cancer immunotherapy
TW202525841A (zh)	2019-06-27	2025-07-01	美國衛生與公眾服務部	識別p53中之r175h或y220c突變之t細胞受體
SG11202111943UA (en)	2019-07-02	2021-11-29	Hutchinson Fred Cancer Res	Recombinant ad35 vectors and related gene therapy improvements
AU2020315796A1 (en) *	2019-07-19	2022-02-24	Memorial Hospital For Cancer And Allied Diseases	Fusion polypeptide for immunotherapy
DE102019121007A1 (de)	2019-08-02	2021-02-04	Immatics Biotechnologies Gmbh	Antigenbindende Proteine, die spezifisch an MAGE-A binden
WO2021035170A1 (en)	2019-08-21	2021-02-25	Precision Biosciences, Inc.	Compositions and methods for tcr reprogramming using fusion proteins
CN112500492B (zh) *	2019-09-13	2023-08-04	中国科学院分子细胞科学卓越创新中心	一种嵌合抗原受体及其用途
EP4038097A1 (de)	2019-10-03	2022-08-10	Cero Therapeutics, Inc.	Chimäre tim4-rezeptoren und verwendungen davon
CN110964122B (zh) *	2019-12-24	2022-04-15	南京北恒生物科技有限公司	T细胞受体融合蛋白及其用途
CA3171906A1 (en)	2020-03-16	2021-09-23	University Of Southern California	Novel antigen binding domains and synthetic antigen receptors incorporating the same
CN115397863A (zh) *	2020-04-01	2022-11-25	基因医疗免疫疗法有限责任公司	Cd3融合蛋白及其用途
WO2021226289A2 (en) *	2020-05-05	2021-11-11	TCR2 Therapeutics Inc.	Compositions and methods for tcr reprogramming using cd70 specific fusion proteins
WO2022020720A1 (en) *	2020-07-24	2022-01-27	TCR2 Therapeutics Inc.	Compositions and methods for treating cancer
WO2022036265A1 (en)	2020-08-14	2022-02-17	Cero Therapeutics, Inc.	Chimeric tim receptors and uses thereof
WO2022036287A1 (en)	2020-08-14	2022-02-17	Cero Therapeutics, Inc.	Anti-cd72 chimeric receptors and uses thereof
WO2022036285A1 (en)	2020-08-14	2022-02-17	Cero Therapeutics, Inc.	Compositions and methods for treating cancer with chimeric tim receptors in combination with inhibitors of poly (adp-ribose) polymerase
US20240018210A1 (en)	2020-11-13	2024-01-18	The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic	Enhanced antigen reactivity of immune cells expressing a mutant non-signaling cd3 zeta chain
CN112521513B (zh) *	2020-12-15	2021-08-24	青岛西凯生物技术有限公司	一种靶向cd19的嵌合抗原受体(car)及其应用
AR124414A1 (es)	2020-12-18	2023-03-22	Century Therapeutics Inc	Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable
WO2022147480A1 (en)	2020-12-30	2022-07-07	Ansun Biopharma, Inc.	Oncolytic virus encoding sialidase and multispecific immune cell engager
WO2022174172A1 (en) *	2021-02-15	2022-08-18	H. Lee Moffitt Cancer Center And Research Institute Inc.	Customized chimeric antigen receptor polypeptides
WO2022177966A1 (en) *	2021-02-16	2022-08-25	TCR2 Therapeutics Inc.	Compositions and methods for the treatment of hiv
EP4301782A1 (de)	2021-03-05	2024-01-10	Go Therapeutics, Inc.	Anti-glyco-cd44-antikörper und deren verwendungen
WO2022192286A1 (en) *	2021-03-09	2022-09-15	TCR2 Therapeutics Inc.	Compositions and methods for tcr reprogramming using fusion proteins and rna interference
WO2022233956A1 (en)	2021-05-05	2022-11-10	Immatics Biotechnologies Gmbh	Antigen binding proteins specifically binding prame
EP4376874B1 (de)	2021-07-28	2026-03-04	Cero Therapeutics Holdings, Inc.	Chimäre tim4-rezeptoren und verwendungen davon
WO2023010436A1 (zh) *	2021-08-05	2023-02-09	卡瑞济(北京)生命科技有限公司	Tcr表达构建体以及其制备方法和用途
US20250101126A1 (en)	2021-08-05	2025-03-27	Go Therapeutics, Inc.	Anti-glyco-muc4 antibodies and their uses
CN118354789A (zh)	2021-09-03	2024-07-16	Go医疗股份有限公司	抗糖-cMET抗体及其用途
EP4396232A1 (de)	2021-09-03	2024-07-10	Go Therapeutics, Inc.	Anti-glyco-lamp1-antikörper und deren verwendungen
WO2023081767A1 (en)	2021-11-05	2023-05-11	Precision Biosciences, Inc.	Methods for immunotherapy
WO2023091910A1 (en)	2021-11-16	2023-05-25	Precision Biosciences, Inc.	Methods for cancer immunotherapy
WO2023108150A1 (en)	2021-12-10	2023-06-15	Precision Biosciences, Inc.	Methods for cancer immunotherapy
WO2023215725A1 (en)	2022-05-02	2023-11-09	Fred Hutchinson Cancer Center	Compositions and methods for cellular immunotherapy
WO2024062138A1 (en)	2022-09-23	2024-03-28	Mnemo Therapeutics	Immune cells comprising a modified suv39h1 gene
WO2024148167A1 (en)	2023-01-05	2024-07-11	Precision Biosciences, Inc.	Optimized engineered meganucleases having specificity for the human t cell receptor alpha constant region gene
PE20252789A1 (es)	2023-05-24	2025-12-22	Kumquat Biosciences Inc	Compuestos heterociclicos y usos de estos
WO2024259371A2 (en) *	2023-06-14	2024-12-19	Duke University	COMPOSITIONS FOR AND METHODS OF EXPANDING γδ T CELLS
WO2025029930A1 (en)	2023-07-31	2025-02-06	Legend Biotech Ireland Limited	Cells overexpressing cd31 and methods of use thereof
WO2025081123A1 (en)	2023-10-12	2025-04-17	Fred Hutchinson Cancer Center	Methods and compositions for improving t cell immunotherapy
WO2025101820A1 (en)	2023-11-08	2025-05-15	Fred Hutchinson Cancer Center	Compositions and methods for cellular immunotherapy
WO2025160480A1 (en)	2024-01-26	2025-07-31	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Enhanced tumor reactivity of t cells lacking sit1, lax1, or trat1
WO2025162379A1 (zh) *	2024-02-01	2025-08-07	深圳市济因生物科技有限公司	一种多肽及包含所述多肽基因的病毒载体
WO2026035951A2 (en)	2024-08-07	2026-02-12	Legend Biotech Ireland Limited	Cells overexpressing cd43 and methods of use thereof
WO2026055226A1 (en)	2024-09-03	2026-03-12	Legend Biotech Ireland Limited	Cells overexpressing b3gnt2 and methods of use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0638119A1 (de) *	1992-03-18	1995-02-15	Yeda Research And Development Co. Ltd.	Chimäre rezeptorgene und entsprechend damit transformierte zellen
WO2010052014A1 (en) *	2008-11-07	2010-05-14	Micromet Ag	Treatment of acute lymphoblastic leukemia
EP2258720A1 (de) *	2009-05-19	2010-12-08	Max Delbrück Centrum für Molekulare Medizin (MDC) Berlin-Buch;	Mehrfachziel-T-Zellen-Rezeptor

Family Cites Families (268)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US1009390A (en)	1910-04-18	1911-11-21	Miehle Printing Press & Mfg	Manufacture of printing-plates.
US1035847A (en)	1910-05-23	1912-08-20	William P Bettendorf	Means for cushioning the bodies of railway-cars.
US1020828A (en)	1911-12-11	1912-03-19	William A Rees	Electric washing-machine.
US1044284A (en)	1912-04-29	1912-11-12	Gen Electric	Heating device.
FR901228A (fr)	1943-01-16	1945-07-20	Deutsche Edelstahlwerke Ag	Système d'aimant à entrefer annulaire
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
US6548640B1 (en)	1986-03-27	2003-04-15	Btg International Limited	Altered antibodies
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
US5906936A (en) *	1988-05-04	1999-05-25	Yeda Research And Development Co. Ltd.	Endowing lymphocytes with antibody specificity
US6534055B1 (en)	1988-11-23	2003-03-18	Genetics Institute, Inc.	Methods for selectively stimulating proliferation of T cells
US5858358A (en)	1992-04-07	1999-01-12	The United States Of America As Represented By The Secretary Of The Navy	Methods for selectively stimulating proliferation of T cells
US6905680B2 (en)	1988-11-23	2005-06-14	Genetics Institute, Inc.	Methods of treating HIV infected subjects
US6352694B1 (en)	1994-06-03	2002-03-05	Genetics Institute, Inc.	Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US5703055A (en)	1989-03-21	1997-12-30	Wisconsin Alumni Research Foundation	Generation of antibodies through lipid mediated DNA delivery
US5399346A (en)	1989-06-14	1995-03-21	The United States Of America As Represented By The Department Of Health And Human Services	Gene therapy
US5585362A (en)	1989-08-22	1996-12-17	The Regents Of The University Of Michigan	Adenovirus vectors for gene therapy
GB8928874D0 (en)	1989-12-21	1990-02-28	Celltech Ltd	Humanised antibodies
EP0519596B1 (de)	1991-05-17	2005-02-23	Merck & Co. Inc.	Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
US5199942A (en)	1991-06-07	1993-04-06	Immunex Corporation	Method for improving autologous transplantation
EP1400536A1 (de)	1991-06-14	2004-03-24	Genentech Inc.	Verfahren zur Herstellung humanisierter Antikörper
US5565332A (en)	1991-09-23	1996-10-15	Medical Research Council	Production of chimeric antibodies - a combinatorial approach
GB9125768D0 (en)	1991-12-04	1992-02-05	Hale Geoffrey	Therapeutic method
EP0571613B1 (de)	1991-12-13	2003-09-17	Xoma Corporation	Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung
GB9203459D0 (en)	1992-02-19	1992-04-08	Scotgen Ltd	Antibodies with germ-line variable regions
WO1993019163A1 (en)	1992-03-18	1993-09-30	Yeda Research And Development Co, Ltd.	Chimeric receptor genes and cells transformed therewith
US5350674A (en)	1992-09-04	1994-09-27	Becton, Dickinson And Company	Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
US5639641A (en)	1992-09-09	1997-06-17	Immunogen Inc.	Resurfacing of rodent antibodies
US7175843B2 (en)	1994-06-03	2007-02-13	Genetics Institute, Llc	Methods for selectively stimulating proliferation of T cells
US5731168A (en)	1995-03-01	1998-03-24	Genentech, Inc.	Method for making heteromultimeric polypeptides
US7067318B2 (en)	1995-06-07	2006-06-27	The Regents Of The University Of Michigan	Methods for transfecting T cells
US6692964B1 (en)	1995-05-04	2004-02-17	The United States Of America As Represented By The Secretary Of The Navy	Methods for transfecting T cells
GB9809658D0 (en)	1998-05-06	1998-07-01	Celltech Therapeutics Ltd	Biological products
EP2011801A1 (de)	1999-05-27	2009-01-07	Government of the United States as represented by the Secretary, Department of Health and Human Services	Immunkonjugate mit hoher Bindungsaffinität
JP2003502341A (ja)	1999-06-16	2003-01-21	マイアロスコーポレイション	白血病阻害因子に由来するレトロ−インベルソなペプチド
HK1047109A1 (zh)	1999-10-15	2003-02-07	University Of Massachusetts	作为指定基因干预工具的rna干预轨迹基因
US6326193B1 (en)	1999-11-05	2001-12-04	Cambria Biosciences, Llc	Insect control agent
KR20030032922A (ko)	2000-02-24	2003-04-26	싸이트 테라피스 인코포레이티드	세포의 동시 자극 및 농축
US6867041B2 (en)	2000-02-24	2005-03-15	Xcyte Therapies, Inc.	Simultaneous stimulation and concentration of cells
US7572631B2 (en)	2000-02-24	2009-08-11	Invitrogen Corporation	Activation and expansion of T cells
US6797514B2 (en)	2000-02-24	2004-09-28	Xcyte Therapies, Inc.	Simultaneous stimulation and concentration of cells
AU2001275474A1 (en)	2000-06-12	2001-12-24	Akkadix Corporation	Materials and methods for the control of nematodes
US6822082B2 (en)	2000-06-30	2004-11-23	Zymogenetics, Inc.	Polynucleotides for mammalian secreted protein, Z1055G2P
ATE338124T1 (de)	2000-11-07	2006-09-15	Hope City	Cd19-spezifische umgezielte immunzellen
CN1294148C (zh)	2001-04-11	2007-01-10	中国科学院遗传与发育生物学研究所	环状单链三特异抗体
JP4213586B2 (ja)	2001-09-13	2009-01-21	株式会社抗体研究所	ラクダ抗体ライブラリーの作製方法
AU2003208839A1 (en)	2002-02-13	2003-09-04	Micromet Ag	De-immunized (poly)peptide constructs
DE10244457A1 (de)	2002-09-24	2004-04-01	Johannes-Gutenberg-Universität Mainz	Verfahren zur rationalen Mutagenese von alpha/beta T-Zell Rezeptoren und entsprechend mutierte MDM2-Protein spezifische alpha/beta T-Zell Rezeptoren
WO2004041863A2 (en)	2002-11-08	2004-05-21	Ablynx N.V.	Single domain antibodies directed against interferon- gamma and uses therefor
US20050129671A1 (en)	2003-03-11	2005-06-16	City Of Hope	Mammalian antigen-presenting T cells and bi-specific T cells
US7251470B2 (en)	2003-06-25	2007-07-31	Nokia Corporation	Emergency response system with personal emergency device
KR20060041205A (ko)	2003-07-01	2006-05-11	이뮤노메딕스, 인코오포레이티드	양특이성 항체들의 다가 담체들
US7902338B2 (en)	2003-07-31	2011-03-08	Immunomedics, Inc.	Anti-CD19 antibodies
EP2272566A3 (de)	2003-08-18	2013-01-02	MedImmune, LLC	Humanisierung von antikörpern
WO2005035575A2 (en)	2003-08-22	2005-04-21	Medimmune, Inc.	Humanization of antibodies
MXPA06004035A (es)	2003-10-16	2006-08-31	Micromet Ag	Aglutinantes cd3 de-inmunizados multi-especificos.
US20130266551A1 (en)	2003-11-05	2013-10-10	St. Jude Children's Research Hospital, Inc.	Chimeric receptors with 4-1bb stimulatory signaling domain
US7982011B2 (en)	2003-11-25	2011-07-19	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Mutated anti-cd22 antibodies and immunoconjugates
US20050238626A1 (en)	2004-04-01	2005-10-27	Lili Yang	Antigen specific T cell therapy
EP1786918A4 (de)	2004-07-17	2009-02-11	Imclone Systems Inc	Neuer tetravalenter bispezifischer antikörper
WO2006018833A2 (en)	2004-08-16	2006-02-23	Tadiran Spectralink Ltd.	A wearable device, system and method for measuring a pulse while a user is in motion
US9707302B2 (en)	2013-07-23	2017-07-18	Immunomedics, Inc.	Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
EP1861425B1 (de)	2005-03-10	2012-05-16	Morphotek, Inc.	Anti-mesothelin-antikörper
EP1885758A2 (de)	2005-05-12	2008-02-13	The Government of the United States of America as Represented by The Department of Health and Human Services	Für immunologische assays geeignete anti-mesothelin-antikörper
NZ612578A (en)	2005-08-19	2014-11-28	Abbvie Inc	Dual variable domain immunoglobin and uses thereof
AT503861B1 (de)	2006-07-05	2008-06-15	F Star Biotech Forsch & Entw	Verfahren zur manipulation von t-zell-rezeptoren
SI2856876T1 (en)	2007-03-30	2018-04-30	Memorial Sloan-Kettering Cancer Center	Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
GB0721686D0 (en)	2007-11-05	2007-12-12	Medinnova As	Polypeptides
MX2010005603A (es)	2007-11-26	2010-08-02	Bayer Schering Pharma Ag	Anticuerpos antimesotelina y usos de los mismos.
WO2009070642A1 (en)	2007-11-28	2009-06-04	Medimmune, Llc	Protein formulation
KR20090092900A (ko)	2008-02-28	2009-09-02	신준호	어린이 및 노약자 안전보호시스템
US20090322513A1 (en)	2008-06-27	2009-12-31	Franklin Dun-Jen Hwang	Medical emergency alert system and method
EP2331566B1 (de)	2008-08-26	2015-10-07	City of Hope	Verfahren und zusammensetzungen zur verstärkung der anti-tumor-effektor-funktion von t-zellen
US9181342B2 (en)	2008-09-12	2015-11-10	Isis Innovation Limited	PD-1 specific antibodies and uses thereof
EP2370467B1 (de)	2008-10-01	2016-09-07	Amgen Research (Munich) GmbH	Cross-species-spezifische bispezifische pscaxcd3-, cd19xcd3-, c-metxcd3-, endosialinxcd3-, epcamxc d3-, igf-1rxcd3- oder fapalpha-xcd3-einzelkettenantikörper
CN102421800A (zh)	2009-02-23	2012-04-18	格兰马克药品股份有限公司	结合cd19的人源化抗体及其用途
MX341884B (es) *	2009-03-10	2016-09-07	Biogen Ma Inc	Anticuerpos anti-antigeno de maduracion de celulas b (bcma).
CA2759733C (en)	2009-04-23	2019-09-03	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Anti-human ror1 antibodies
US20130066283A1 (en)	2009-10-23	2013-03-14	Nexisvision, Inc.	Corneal Denervation for Treatment of Ocular Pain
WO2011059836A2 (en)	2009-10-29	2011-05-19	Trustees Of Dartmouth College	T cell receptor-deficient t cell compositions
EP2361936B1 (de)	2010-02-25	2016-04-20	Affimed GmbH	Molécule à liaison d'antigène et ses utilisations
CA3255551A1 (en)	2010-03-26	2025-04-15	Memorial Sloan-Kettering Cancer Center	MUC16 ANTIBODIES AND METHODS OF USE
EP2593796A4 (de)	2010-07-16	2016-07-27	Auckland Uniservices Ltd	Bakterielle nitroreduktase-enzyme und verfahren dafür
WO2012033885A1 (en)	2010-09-08	2012-03-15	Baylor College Of Medicine	Immunotherapy of cancer using genetically engineered gd2-specific t cells
MX2013004792A (es)	2010-10-27	2013-08-27	Baylor College Medicine	Receptor cd27 quimericos para redirigir celulas t a malignidades cd70-positivas.
CN103459425B (zh)	2010-10-27	2015-11-25	安进研发（慕尼黑）股份有限公司	用于治疗dlbcl的组合物
ES2657970T3 (es)	2010-12-01	2018-03-07	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Anticuerpos contra ROR1 de conejo/ser humano quiméricos
PH12013501201A1 (en)	2010-12-09	2013-07-29	Univ Pennsylvania	Use of chimeric antigen receptor-modified t cells to treat cancer
GB201020995D0 (en)	2010-12-10	2011-01-26	Bioinvent Int Ab	Biological materials and uses thereof
BR112013014527A2 (pt)	2010-12-20	2017-03-07	Genentech Inc	anticorpo isolado, ácido nucleico isolado, célula hospedeira, método para produzir um anticorpo, imunoconjugado, formulação farmacêutica, uso do imunoconjugado, método para tratamento de um indivíduo que tem um câncer positivo para mesotelina, para inibição de proliferação de uma célula positiva para mesotelina, para detecção de mesotelina humana em uma amostra biológica e para detectar um câncer positivo para mesotelina
EP3604339B1 (de)	2011-01-14	2021-03-10	The Regents Of The University Of California	Therapeutische antikörper gegen das ror-1-protein und verfahren zur verwendung davon
KR20140004174A (ko)	2011-01-18	2014-01-10	더 트러스티스 오브 더 유니버시티 오브 펜실바니아	암 치료를 위한 조성물 및 방법
KR101551555B1 (ko)	2011-03-17	2015-09-08	밀테니 비오텍 게앰베하	Tcr 알파/베타가 고갈된 세포 제제
CA2832540C (en)	2011-04-08	2020-09-15	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Anti-epidermal growth factor receptor variant iii chimeric antigen receptors and use of same for the treatment of cancer
CN103946952A (zh)	2011-09-16	2014-07-23	宾夕法尼亚大学董事会	用于治疗癌症的rna改造的t细胞
US9688740B2 (en)	2011-10-26	2017-06-27	National Cancer Center	Mutant CTLA4 gene transfected T cell and composition including same for anticancer immunotherapy
US9272002B2 (en)	2011-10-28	2016-03-01	The Trustees Of The University Of Pennsylvania	Fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
US9422351B2 (en)	2011-11-03	2016-08-23	The Trustees Of The University Of Pennsylvania	Isolated B7-H4 specific compositions and methods of use thereof
WO2013070468A1 (en)	2011-11-08	2013-05-16	The Trustees Of The University Of Pennsylvania	Glypican-3-specific antibody and uses thereof
TWI679212B (zh)	2011-11-15	2019-12-11	美商安進股份有限公司	針對ｂｃｍａ之e3以及ｃｄ３的結合分子
UY34504A (es)	2011-12-09	2013-06-28	Amgen Res Munich Gmbh	Prevención de los efectos adversos causados por los anticuerpos biespecíficos EpCAMxCD3
CA2861491C (en)	2012-02-13	2020-08-25	Seattle Children's Hospital D/B/A Seattle Children's Research Institute	Bispecific chimeric antigen receptors and therapeutic uses thereof
WO2013126729A1 (en) *	2012-02-22	2013-08-29	The Trustees Of The University Of Pennsylvania	Use of the cd2 signaling domain in second-generation chimeric antigen receptors
CA3285826A1 (en)	2012-02-22	2026-03-02	The Trustees Of The University Of Pennsylvania	Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer
EP2828290B1 (de)	2012-03-23	2018-08-15	The United States of America, represented by the Secretary, Department of Health and Human Services	Chimäre anti-mesothelin-antigenrezeptoren
RU2766608C2 (ru)	2012-04-11	2022-03-15	Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез	Химерные антигенные рецепторы, нацеленные на антиген созревания b-клеток
US20130280220A1 (en)	2012-04-20	2013-10-24	Nabil Ahmed	Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes
US9127081B2 (en)	2012-05-10	2015-09-08	Washington University	Tumor targeted TNF-related apoptosis inducing ligand fusion polypeptide and nucleic acids encoding the same
BR112014029417B1 (pt) *	2012-05-25	2023-03-07	Cellectis	Método ex vivo para a preparação de células t para imunoterapia
EP2872617A4 (de)	2012-07-13	2015-12-09	Univ Pennsylvania	Epitopstreuung in zusammenhang mit car-t-zellen
JP2015524255A (ja)	2012-07-13	2015-08-24	ザトラスティーズオブザユニバーシティオブペンシルバニア	二重特異性抗体を共導入することによってｃａｒｔ細胞の活性を強化する方法
JP6482461B2 (ja)	2012-07-13	2019-03-13	ザトラスティーズオブザユニバーシティオブペンシルバニア	投与に関する形質導入ｔ細胞の適合性の評価方法
BR122020002986A8 (pt)	2012-08-20	2023-04-18	Seattle Childrens Hospital Dba Seattle Childrens Res Inst	Método e composições para imunoterapia celular
CN104955845B (zh)	2012-09-27	2018-11-16	美国政府(由卫生和人类服务部的部长所代表)	间皮素抗体和引起有效的抗肿瘤活性的方法
WO2014055442A2 (en)	2012-10-01	2014-04-10	The Trustees Of The University Of Pennsylvania	Compositions and methods for targeting stromal cells for the treatment of cancer
MX370148B (es)	2012-10-02	2019-12-03	Memorial Sloan Kettering Cancer Center	Composiciones y su uso para inmunoterapia.
WO2014055657A1 (en)	2012-10-05	2014-04-10	The Trustees Of The University Of Pennsylvania	Use of a trans-signaling approach in chimeric antigen receptors
US9562110B2 (en)	2012-11-21	2017-02-07	Wuhan Yzy Biopharma Co., Ltd.	Bispecific antibody
US8697359B1 (en)	2012-12-12	2014-04-15	The Broad Institute, Inc.	CRISPR-Cas systems and methods for altering expression of gene products
US20150329640A1 (en)	2012-12-20	2015-11-19	Bluebird Bio, Inc.	Chimeric antigen receptors and immune cells targeting b cell malignancies
WO2014122143A1 (en)	2013-02-05	2014-08-14	Engmab Ag	Method for the selection of antibodies against bcma
CN113005091A (zh)	2013-02-06	2021-06-22	细胞基因公司	具有改进特异性的修饰的t淋巴细胞
DK2956175T3 (da)	2013-02-15	2017-11-27	Univ California	Kimærisk antigenreceptor og fremgangsmåder til anvendelse deraf
US9573988B2 (en) *	2013-02-20	2017-02-21	Novartis Ag	Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells
EP2961773B1 (de)	2013-02-26	2019-03-20	Roche Glycart AG	Bispezifische antigenbindende moleküle zur t-zellen-aktivierung
CN113684185A (zh)	2013-02-26	2021-11-23	纪念斯隆-凯特琳癌症中心	用于免疫疗法的组合物和方法
WO2014134412A1 (en)	2013-03-01	2014-09-04	Regents Of The University Of Minnesota	Talen-based gene correction
WO2014138306A1 (en)	2013-03-05	2014-09-12	Baylor College Of Medicine	Engager cells for immunotherapy
AR095374A1 (es)	2013-03-15	2015-10-14	Amgen Res Munich Gmbh	Moléculas de unión para bcma y cd3
IL311390A (en)	2013-03-15	2024-05-01	Memorial Sloan Kettering Cancer Center	Preparations and methods for immunotherapy
US10150800B2 (en)	2013-03-15	2018-12-11	Zyngenia, Inc.	EGFR-binding modular recognition domains
US9446105B2 (en)	2013-03-15	2016-09-20	The Trustees Of The University Of Pennsylvania	Chimeric antigen receptor specific for folate receptor β
JP6493692B2 (ja)	2013-03-15	2019-04-10	セルジーンコーポレイション	修飾されたｔリンパ球
UY35468A (es)	2013-03-16	2014-10-31	Novartis Ag	Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
WO2014165707A2 (en)	2013-04-03	2014-10-09	Memorial Sloan-Kettering Cancer Center	Effective generation of tumor-targeted t-cells derived from pluripotent stem cells
FI2997141T3 (fi)	2013-05-13	2022-12-15		CD19-spesifinen kimeerinen antigeenireseptori ja sen käyttöjä
US11311575B2 (en)	2013-05-13	2022-04-26	Cellectis	Methods for engineering highly active T cell for immunotherapy
CA2913052A1 (en)	2013-05-24	2014-11-27	Board Of Regents, The University Of Texas System	Chimeric antigen receptor-targeting monoclonal antibodies
ES2883131T3 (es)	2013-05-29	2021-12-07	Cellectis	Métodos para la modificación de células T para inmunoterapia utilizando el sistema de nucleasa CAS guiado por ARN
WO2014191128A1 (en)	2013-05-29	2014-12-04	Cellectis	Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system
WO2015006749A2 (en)	2013-07-12	2015-01-15	Zymeworks Inc.	Bispecific cd3 and cd19 antigen binding contructs
EP3027755B1 (de)	2013-08-02	2019-10-09	The Regents of The University of California	Manipulation von antiviraler t-zell-immunität durch stammzellen und chimäre antigenrezeptoren
NZ718283A (en)	2013-09-25	2022-05-27	Cytomx Therapeutics Inc	Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereof
GB201317929D0 (en)	2013-10-10	2013-11-27	Ucl Business Plc	Chimeric antigen receptor
CN105814083A (zh)	2013-10-15	2016-07-27	加州生物医学研究所	嵌合抗原受体t细胞开关和其用途
CN105829349B (zh)	2013-10-15	2023-02-03	斯克利普斯研究所	肽嵌合抗原受体t细胞开关和其用途
WO2015092024A2 (en)	2013-12-20	2015-06-25	Cellectis	Method of engineering multi-input signal sensitive t cell for immunotherapy
NZ759969A (en)	2013-12-20	2022-12-23	Fred Hutchinson Cancer Center	Tagged chimeric effector molecules and receptors thereof
EP3087101B1 (de)	2013-12-20	2024-06-05	Novartis AG	Regulierbarer chimärer antigenrezeptor
US10519251B2 (en)	2013-12-30	2019-12-31	Epimab Biotherapeutics, Inc.	Fabs-in-tandem immunoglobulin and uses thereof
ES2701846T3 (es)	2014-01-14	2019-02-26	Cellectis	Receptor de antígeno quimérico que usa dominios de reconocimiento de antígenos derivados de pez cartilaginoso
WO2015112626A1 (en) *	2014-01-21	2015-07-30	June Carl H	Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
TWI681969B (zh)	2014-01-23	2020-01-11	美商再生元醫藥公司	針對ｐｄ-１的人類抗體
US20160333422A1 (en)	2014-01-24	2016-11-17	The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv	Anti-ny-br-1 polypeptides, proteins, and chimeric antigen receptors
AU2015214145A1 (en)	2014-02-04	2016-08-25	Kite Pharma. Inc.	Methods for producing autologous T cells useful to treat B cell malignancies and other cancers and compositions thereof
KR102375998B1 (ko)	2014-02-14	2022-03-21	더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템	키메라 항원 수용체 및 제조방법
WO2015121454A1 (en)	2014-02-14	2015-08-20	Cellectis	Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells
CA2939711C (en)	2014-02-21	2020-09-29	Cellectis	Method for in situ inhibition of regulatory t cells
CA2935748A1 (en)	2014-02-25	2015-09-03	Immunomedics, Inc.	Humanized rfb4 anti-cd22 antibody
KR101605421B1 (ko)	2014-03-05	2016-03-23	국립암센터	B 세포 림프종 세포를 특이적으로 인지하는 단일클론항체 및 이의 용도
ES2857226T3 (es)	2014-03-15	2021-09-28	Novartis Ag	Receptor de antígeno quimérico regulable
US20170335281A1 (en)	2014-03-15	2017-11-23	Novartis Ag	Treatment of cancer using chimeric antigen receptor
PT3514172T (pt)	2014-04-01	2020-04-21	Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh	Imunorrecetores específicos de claudina-6 e epítopos de células t
EP3131927B8 (de)	2014-04-14	2020-12-23	Cellectis	Bcma (cd269) -spezifische chimäre antigenrezeptoren für krebsimmuntherapie
PL3134432T3 (pl)	2014-04-25	2020-10-19	Bluebird Bio, Inc.	Promotor mnd chimeryczne receptory antygenowe
HUE049514T2 (hu)	2014-04-25	2020-09-28	Bluebird Bio Inc	Javított eljárások adoptív sejtterápiák kialakítására
CN113604491A (zh)	2014-05-02	2021-11-05	宾夕法尼亚大学董事会	嵌合自身抗体受体t细胞的组合物和方法
WO2015179801A1 (en)	2014-05-23	2015-11-26	University Of Florida Research Foundation, Inc.	Car based immunotherapy
US10287360B2 (en)	2014-05-23	2019-05-14	INSERM (Institut National de la Santé et de la Recherche Médicale	Anti-EGFR conformational single domain antibodies and uses thereof
EP4166148B1 (de)	2014-06-06	2026-02-18	Memorial Sloan-Kettering Cancer Center	Gegen mesothelin gerichete chimäre antigenrezeptoren und verwendungen davon
KR20170032406A (ko)	2014-07-15	2017-03-22	주노 쎄러퓨티크스 인코퍼레이티드	입양 세포 치료를 위한 조작된 세포
BR112017001183A2 (pt)	2014-07-21	2017-11-28	Novartis Ag	tratamento de câncer usando receptor de antígeno quimérico anti-bcma humanizado
ES2878449T3 (es)	2014-07-24	2021-11-18	2Seventy Bio Inc	Receptores antigénicos quiméricos de BCMA
WO2016016344A1 (en)	2014-07-29	2016-02-04	Cellectis	Ror1(ntrkr1)specific chimeric antigen receptors for cancer immunotherapy
EP2982692A1 (de)	2014-08-04	2016-02-10	EngMab AG	Bispezifische Antikörper gegen CD3-Epsilon und BCMA
EP3177711B1 (de)	2014-08-07	2024-04-24	Northwestern University	Verwendung von liganden für zu festen trägern konjugierten rezeptor für programmierten zelltod zur expansion von humanen regulatorischen t-zellen
WO2016019969A1 (en)	2014-08-08	2016-02-11	Ludwig-Maximilians-Universität München	Subcutaneously administered bispecific antibodies for use in the treatment of cancer
PT3177640T (pt)	2014-08-08	2020-08-31	Univ Leland Stanford Junior	Agentes pd-1 de alta afinidade e métodos de utilização
US20180080008A1 (en)	2014-08-12	2018-03-22	Anthrogenesis Corporation	Car-t lymphocytes engineered to home to lymph node b cell zone, skin, or gastrointestinal tract
DK4074735T3 (da)	2014-08-28	2025-07-14	Bioatla Inc	Betinget aktive kimæriske antigenreceptorer til modificerede t-celler
GB201415347D0 (en)	2014-08-29	2014-10-15	Ucl Business Plc	Signalling system
WO2016036678A1 (en)	2014-09-02	2016-03-10	Medimmune, Llc	Formulations of bispecific antibodies
CA2972714A1 (en)	2014-09-09	2016-03-17	Unum Therapeutics	Chimeric receptors and uses thereof in immune therapy
BR112017005631A2 (pt)	2014-09-19	2018-06-26	City Of Hope	células t com receptor de antígeno coestimulador quimérico direcionadas à il13ra2
WO2016054520A2 (en) *	2014-10-03	2016-04-07	The California Institute For Biomedical Research	Engineered cell surface proteins and uses thereof
BR112017007003A2 (pt)	2014-10-07	2017-12-19	Cellectis	método para modulação de atividade de células imunes induzidas por car
MX392487B (es)	2014-10-20	2025-03-21	Juno Therapeutics Inc	Métodos y composiciones para dosificación en terapia celular adoptiva.
CA2964958A1 (en) †	2014-10-31	2016-05-06	The Trustees Of The University Of Pennsylvania	Methods and compositions for modified t cells
WO2016073381A1 (en)	2014-11-03	2016-05-12	Cerus Corporation	Compositions and methods for improved car-t cell therapies
ES2987570T3 (es)	2014-11-05	2024-11-15	Juno Therapeutics Inc	Métodos para la transducción y el procesamiento de células
EP3023437A1 (de)	2014-11-20	2016-05-25	EngMab AG	Bispezifische Antikörper gegen CD3epsilon und BCMA
DK3221357T3 (da)	2014-11-20	2020-08-10	Hoffmann La Roche	Fælles letkæder og fremgangsmåder til anvendelse
US10201606B2 (en)	2014-11-26	2019-02-12	Miltenyi Biotec Gmbh	Combination immunotherapy of antigen-recognizing receptors and hematopoietic cells for the treatment of diseases
EP3029067A1 (de)	2014-12-01	2016-06-08	Deutsches Krebsforschungszentrum	Verwendung von blockierenden Reagenzien zur Verringerung von unspezifischer T-Zellenaktivierung
EP3029068A1 (de)	2014-12-03	2016-06-08	EngMab AG	Bispezifische Antikörper gegen CD3-Epsilon-BCMA und zur Verwendung bei der Behandlung von Krankheiten
ES2819553T3 (es)	2014-12-03	2021-04-16	Juno Therapeutics Inc	Métodos y composiciones para terapia celular adoptiva
US20180334490A1 (en)	2014-12-03	2018-11-22	Qilong H. Wu	Methods for b cell preconditioning in car therapy
SI3226897T1 (sl)	2014-12-05	2021-08-31	Memorial Sloan Kettering Cancer Center	Protitelesa, ki ciljajo na B-celični maturacijski antigen, in postopki uporabe
CN118271463A (zh)	2014-12-05	2024-07-02	纪念斯隆-凯特琳癌症中心	靶向g-蛋白偶联受体的嵌合抗原受体及其用途
MY191537A (en)	2014-12-05	2022-06-30	Memorial Sloan Kettering Cancer Center	Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof
CA2969384A1 (en)	2014-12-17	2016-06-23	Cellectis	Inhibitory chimeric antigen receptor (icar or n-car) expressing non-t cell transduction domain
EP3037170A1 (de)	2014-12-27	2016-06-29	Miltenyi Biotec GmbH	Multisort-Zelltrennverfahren
RU2021118125A (ru)	2014-12-29	2022-04-06	Новартис Аг	Способы получения экспрессирующих химерный антигенный рецептор клеток
CA2973720A1 (en)	2015-01-14	2016-07-21	Compass Therapeutics Llc	Multispecific immunomodulatory antigen-binding constructs
ES2818103T3 (es)	2015-01-16	2021-04-09	Juno Therapeutics Inc	Anticuerpos y receptores de antígenos quiméricos específicos para ROR1
US11459390B2 (en)	2015-01-16	2022-10-04	Novartis Ag	Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor
GB201501175D0 (en)	2015-01-23	2015-03-11	Univ Oslo Hf	A universal T-cell for personalised medicine
WO2016123143A1 (en)	2015-01-26	2016-08-04	The University Of Chicago	CAR T-CELLS RECOGNIZING CANCER-SPECIFIC IL 13Rα2
WO2016126608A1 (en)	2015-02-02	2016-08-11	Novartis Ag	Car-expressing cells against multiple tumor antigens and uses thereof
EP3253414A4 (de)	2015-02-05	2018-07-11	The University Of Queensland	Zielkonstrukte zur lieferung von nutzlasten
CN107635578A (zh)	2015-02-05	2018-01-26	Stc.Unm 公司	抗前‑bcr拮抗剂和方法
US20160228547A1 (en)	2015-02-06	2016-08-11	Batu Biologics, Inc.	Chimeric antigen receptor targeting of tumor endothelium
EP3256492A4 (de)	2015-02-09	2018-07-11	University of Florida Research Foundation, Inc.	Bispezifischer chimärer antigenrezeptor und verwendungen davon
WO2016127257A1 (en)	2015-02-12	2016-08-18	University Health Network	Chimeric antigen receptors
US20160237407A1 (en)	2015-02-17	2016-08-18	Batu Biologics, Inc.	Universal donor chimeric antigen receptor cells
EP3865139B1 (de)	2015-02-18	2023-05-03	Enlivex Therapeutics Rdo Ltd	Kombinationsimmuntherapie und cytokinkontrolltherapie zur krebsbehandlung
KR102624023B1 (ko)	2015-02-24	2024-01-11	더 리젠츠 오브 더 유니버시티 오브 캘리포니아	결합-촉발된 전사 스위치 및 이들의 이용 방법
WO2016138846A1 (en)	2015-03-02	2016-09-09	Shanghai Sidansai Biotechnology Co., Ltd	Reducing immune tolerance induced by pd‐l1
EP4406604A3 (de)	2015-03-05	2024-10-23	Fred Hutchinson Cancer Center	Immunmodulatorische fusionsproteine und verwendungen davon
GB201504840D0 (en)	2015-03-23	2015-05-06	Ucl Business Plc	Chimeric antigen receptor
CA2981304C (en)	2015-04-02	2024-01-02	Memorial Sloan Kettering Cancer Center	Tnfrsf14/hvem proteins and methods of use thereof
PL3298033T5 (pl)	2015-05-18	2023-10-30	TCR2 Therapeutics Inc.	Kompozycje i zastosowania medyczne do reprogramowania TCR z zastosowaniem białek fuzyjnych
DK3909972T5 (da)	2015-06-19	2024-08-05	Sebastian Kobold	Pd1-cd28-fusionsproteiner og disses anvendelse i medicin
KR20180019725A (ko)	2015-06-23	2018-02-26	메모리얼 슬로안-케터링 캔서 센터	신규의 피디 1 면역 조절제
JP2018520679A (ja)	2015-06-29	2018-08-02	ザ・ジョンズ・ホプキンス・ユニバーシティー	免疫チェックポイントキメラ抗原受容体療法
CA2997551A1 (en)	2015-09-04	2017-03-09	Memorial Sloan Kettering Cancer Center	Immune cell compositions and methods of use
CN106519037B (zh)	2015-09-11	2019-07-23	科济生物医药（上海）有限公司	可活化的嵌合受体
JP6816133B2 (ja)	2015-10-05	2021-01-20	プレシジョンバイオサイエンシズ，インク．	改変ヒトｔ細胞受容体アルファ定常領域遺伝子を含む遺伝子改変細胞
MX2018004721A (es)	2015-10-23	2018-07-06	Eureka Therapeutics Inc	Construcciones quimericas anticuerpo/receptor de celulas t y usos de las mismas.
US11020429B2 (en)	2015-11-05	2021-06-01	Juno Therapeutics, Inc.	Vectors and genetically engineered immune cells expressing metabolic pathway modulators and uses in adoptive cell therapy
CN105331585A (zh)	2015-11-13	2016-02-17	科济生物医药（上海）有限公司	携带pd-l1阻断剂的嵌合抗原受体修饰的免疫效应细胞
JP7123794B2 (ja)	2015-12-09	2022-08-23	メモリアルスローンケタリングキャンサーセンター	免疫細胞組成物及びそれを使用する方法
EP4643874A3 (de)	2015-12-22	2026-02-11	Novartis AG	Chimärer antigenrezeptor (car) gegen mesothelin und antikörper gegen pd-l1-inhibitor zur kombinierten verwendung in der antikrebstherapie
CN108601841A (zh)	2016-02-10	2018-09-28	免疫医疗公司	Abcg2抑制剂与sacituzumab govitecan(immu-132)的组合克服表达trop-2的癌中对sn-38的抗性
WO2017162587A1 (en)	2016-03-22	2017-09-28	F. Hoffmann-La Roche Ag	Protease-activated t cell bispecific molecules
EP3433269B1 (de)	2016-03-23	2023-09-27	Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)	Fusionsproteine von pd-1 und 4-1bb
ES2891578T3 (es)	2016-04-01	2022-01-28	Kite Pharma Inc	Antígeno quimérico y receptores de células T y métodos de uso
WO2017214452A1 (en)	2016-06-08	2017-12-14	Xencor, Inc.	Treatment of igg4-related diseases with anti-cd19 antibodies crossbinding to cd32b
CA3032498A1 (en)	2016-08-02	2018-02-08	TCR2 Therapeutics Inc.	Compositions and methods for tcr reprogramming using fusion proteins
CN109863242A (zh)	2016-08-30	2019-06-07	纪念斯隆-凯特林癌症中心	用于治疗病毒感染和其它感染的免疫细胞组合物和使用方法
WO2018067993A1 (en)	2016-10-07	2018-04-12	TCR2 Therapeutics Inc.	Compositions and methods for t-cell receptors reprogramming using fusion proteins
JP7291396B2 (ja)	2016-11-22	2023-06-15	ティーシーアール２セラピューティクスインク．	融合タンパク質を用いたｔｃｒの再プログラミングのための組成物及び方法
JP2020513754A (ja)	2016-12-21	2020-05-21	ティーシーアール２セラピューティクスインク．	がん治療用に操作されたｔ細胞
AU2017382243A1 (en)	2016-12-22	2019-05-02	Windmil Therapeutics, Inc.	Compositions and methods for modulating the immune system
WO2018133877A1 (zh)	2017-01-23	2018-07-26	科济生物医药（上海）有限公司	靶向bcma的抗体及其应用
WO2018189360A1 (en)	2017-04-13	2018-10-18	Cellectis	New sequence specific reagents targeting ccr5 in primary hematopoietic cells
JP7538601B2 (ja)	2017-04-26	2024-08-22	ユーリカセラピューティックス，インコーポレイテッド	キメラ活性化受容体及びキメラ刺激受容体を発現する細胞並びにその使用
WO2018232020A1 (en)	2017-06-13	2018-12-20	TCR2 Therapeutics Inc.	Compositions and methods for tcr reprogramming using fusion proteins
WO2019067805A1 (en)	2017-09-27	2019-04-04	University Of Southern California	NEW PLATFORMS FOR CO-STIMULATION, NEW CAR DESIGNS AND OTHER IMPROVEMENTS FOR ADOPTIVE CELL THERAPY
GB201800298D0 (en)	2018-01-09	2018-02-21	Autolus Ltd	Method
CN112020518A (zh)	2018-02-01	2020-12-01	辉瑞公司	靶向cd70的嵌合抗原受体
MX2020009371A (es)	2018-03-09	2021-01-08	Tcr2 Therapeutics Inc	Composiciones y métodos para la reprogramación de tcr mediante el uso de proteínas de fusión.
WO2019222275A2 (en)	2018-05-14	2019-11-21	TCR2 Therapeutics Inc.	Compositions and methods for tcr reprogramming using inducible fusion proteins
BR112021001338A2 (pt)	2018-07-26	2021-05-04	TCR2 Therapeutics Inc.	composições e métodos para reprogramação de tcr usando proteínas de fusão específicas para o alvo
CA3111087A1 (en)	2018-08-29	2020-03-05	Nanjing Legend Biotech Co., Ltd.	Anti-mesothelin chimeric antigen receptor (car) constructs and uses thereof
KR20210069048A (ko)	2018-08-30	2021-06-10	티씨알2 테라퓨틱스 인크.	융합 단백질을 이용하는 tcr 재프로그래밍을 위한 조성물 및 방법
WO2020198033A1 (en)	2019-03-22	2020-10-01	TCR2 Therapeutics Inc.	Compositions and methods for tcr reprogramming using fusion proteins
US20220362295A1 (en)	2019-04-22	2022-11-17	TCR2 Therapeutics Inc.	Compositions and methods for tcr reprogramming using fusion proteins
US20210130438A1 (en)	2019-10-28	2021-05-06	The Broad Institute, Inc.	Pan-cancer t cell exhaustion genes
US20230338421A1 (en)	2020-01-10	2023-10-26	TCR2 Therapeutics Inc.	Compositions and methods for autoimmunity regulation
WO2021155034A1 (en)	2020-01-29	2021-08-05	TCR2 Therapeutics Inc.	Compositions and methods for tcr reprogramming using muc16 specific fusion proteins
WO2021226289A2 (en)	2020-05-05	2021-11-11	TCR2 Therapeutics Inc.	Compositions and methods for tcr reprogramming using cd70 specific fusion proteins
WO2022020720A1 (en)	2020-07-24	2022-01-27	TCR2 Therapeutics Inc.	Compositions and methods for treating cancer
WO2022056321A1 (en)	2020-09-10	2022-03-17	TCR2 Therapeutics Inc.	Compositions and methods for tcr reprogramming using gpc3 specific fusion proteins
WO2022177966A1 (en)	2021-02-16	2022-08-25	TCR2 Therapeutics Inc.	Compositions and methods for the treatment of hiv
US20230065936A1 (en)	2021-04-09	2023-03-02	Tcr2 Therapeutics Inc	Compositions and methods for treating cancer
WO2023044039A1 (en)	2021-09-16	2023-03-23	TCR2 Therapeutics Inc.	Compositions and methods for treating cancer

2016
- 2016-05-18 PL PL16797244.7T patent/PL3298033T5/pl unknown
- 2016-05-18 HU HUE16797244A patent/HUE051661T2/hu unknown
- 2016-05-18 PT PT167972447T patent/PT3298033T/pt unknown
- 2016-05-18 EP EP16797244.7A patent/EP3298033B2/de active Active
- 2016-05-18 EA EA202090931A patent/EA202090931A3/ru unknown
- 2016-05-18 IL IL303905A patent/IL303905A/en unknown
- 2016-05-18 IL IL255697A patent/IL255697B2/en unknown
- 2016-05-18 MX MX2017014822A patent/MX2017014822A/es unknown
- 2016-05-18 FI FIEP16797244.7T patent/FI3298033T4/fi active
- 2016-05-18 CN CN202210028922.8A patent/CN114634943A/zh active Pending
- 2016-05-18 ES ES16797244T patent/ES2819976T5/es active Active
- 2016-05-18 AU AU2016264323A patent/AU2016264323B2/en active Active
- 2016-05-18 SG SG10201914069SA patent/SG10201914069SA/en unknown
- 2016-05-18 BR BR112017024757-7A patent/BR112017024757A2/pt not_active IP Right Cessation
- 2016-05-18 KR KR1020177036173A patent/KR20180029201A/ko not_active Ceased
- 2016-05-18 DK DK16797244.7T patent/DK3298033T4/da active
- 2016-05-18 WO PCT/US2016/033146 patent/WO2016187349A1/en not_active Ceased
- 2016-05-18 JP JP2017560616A patent/JP2018515123A/ja not_active Withdrawn
- 2016-05-18 EP EP18207665.3A patent/EP3466967A1/de not_active Withdrawn
- 2016-05-18 EA EA201792420A patent/EA035618B1/ru unknown
- 2016-05-18 EP EP20180627.0A patent/EP3770168A1/de not_active Withdrawn
- 2016-05-18 CN CN201680032042.0A patent/CN107995913B/zh active Active
2017
- 2017-01-30 US US15/419,398 patent/US10442849B2/en active Active
- 2017-11-24 ZA ZA2017/08000A patent/ZA201708000B/en unknown
2018
- 2018-04-27 US US15/965,739 patent/US10358474B2/en active Active
- 2018-04-27 US US15/965,738 patent/US10358473B2/en active Active
2019
- 2019-06-10 US US16/436,110 patent/US20210206827A9/en not_active Abandoned
2020
- 2020-08-10 US US16/989,602 patent/US11028142B2/en active Active
2021
- 2021-05-13 AU AU2021203052A patent/AU2021203052A1/en not_active Abandoned
- 2021-07-29 JP JP2021124590A patent/JP7047172B2/ja active Active
- 2021-08-26 JP JP2021138030A patent/JP7262535B2/ja active Active
2022
- 2022-12-21 US US18/069,749 patent/US11965012B2/en active Active
2023
- 2023-04-07 JP JP2023062797A patent/JP2023085509A/ja active Pending
2024
- 2024-03-08 US US18/600,309 patent/US20240301026A1/en active Pending

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0638119A1 (de) *	1992-03-18	1995-02-15	Yeda Research And Development Co. Ltd.	Chimäre rezeptorgene und entsprechend damit transformierte zellen
WO2010052014A1 (en) *	2008-11-07	2010-05-14	Micromet Ag	Treatment of acute lymphoblastic leukemia
EP2258720A1 (de) *	2009-05-19	2010-12-08	Max Delbrück Centrum für Molekulare Medizin (MDC) Berlin-Buch;	Mehrfachziel-T-Zellen-Rezeptor

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MOSQUERA LUIS A ET AL: "In vitro and in vivo characterization of a novel antibody-like single-chain TCR human IgG1 fusion protein", THE JOURNAL OF IMMUNOLOGY, THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, vol. 174, no. 7, 1 April 2005 (2005-04-01), pages 4381 - 4388, XP002504087, ISSN: 0022-1767 *
SOMMERMEYER DANIEL ET AL: "Designer T cells by T cell receptor replacement", EUROPEAN JOURNAL OF IMMUNOLOGY NOV 2006,, vol. 36, no. 11, 1 November 2006 (2006-11-01), pages 3052 - 3059, XP002550367, DOI: 10.1002/EJI.200636539 *

Also Published As

Publication number	Publication date
JP7262535B2 (ja)	2023-04-21
IL255697B2 (en)	2023-11-01
AU2016264323A8 (en)	2017-12-21
US20170166622A1 (en)	2017-06-15
US20240301026A1 (en)	2024-09-12
ZA201708000B (en)	2025-04-30
EP3298033B2 (de)	2023-07-12
EA202090931A2 (ru)	2020-07-31
US20200207828A1 (en)	2020-07-02
CN107995913A (zh)	2018-05-04
US11028142B2 (en)	2021-06-08
JP2023085509A (ja)	2023-06-20
US20200362011A1 (en)	2020-11-19
EP3298033A1 (de)	2018-03-28
JP2018515123A (ja)	2018-06-14
EA202090931A3 (ru)	2020-10-30
US10442849B2 (en)	2019-10-15
CN114634943A (zh)	2022-06-17
US10358473B2 (en)	2019-07-23
PT3298033T (pt)	2020-09-22
US20180251514A1 (en)	2018-09-06
US10358474B2 (en)	2019-07-23
US20180244747A1 (en)	2018-08-30
US20210206827A9 (en)	2021-07-08
EA035618B1 (ru)	2020-07-16
ES2819976T5 (es)	2024-02-23
FI3298033T4 (fi)	2023-09-22
US20230235010A1 (en)	2023-07-27
AU2021203052A1 (en)	2021-06-10
EA201792420A1 (ru)	2018-04-30
CA2986254A1 (en)	2016-11-24
US11965012B2 (en)	2024-04-23
PL3298033T3 (pl)	2021-02-22
JP7047172B2 (ja)	2022-04-04
EP3466967A1 (de)	2019-04-10
HUE051661T2 (hu)	2021-03-29
DK3298033T4 (da)	2023-10-02
IL303905A (en)	2023-08-01
PL3298033T5 (pl)	2023-10-30
EP3770168A1 (de)	2021-01-27
CN107995913B (zh)	2022-02-11
AU2016264323A1 (en)	2017-12-14
KR20180029201A (ko)	2018-03-20
JP2021176326A (ja)	2021-11-11
JP2021184749A (ja)	2021-12-09
IL255697B1 (en)	2023-07-01
ES2819976T3 (es)	2021-04-19
WO2016187349A1 (en)	2016-11-24
SG10201914069SA (en)	2020-03-30
HK1252643A1 (en)	2019-05-31
BR112017024757A2 (pt)	2018-11-13
MX2017014822A (es)	2018-04-30
AU2016264323B2 (en)	2021-02-18
EP3298033B1 (de)	2020-08-05
IL255697A (en)	2018-01-31

Legal Events

Date	Code	Title	Description
2016-11-25	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE
2018-02-23	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2018-02-23	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE
2018-03-28	17P	Request for examination filed	Effective date: 20171212
2018-03-28	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2018-03-28	AX	Request for extension of the european patent	Extension state: BA ME
2018-08-22	DAV	Request for validation of the european patent (deleted)
2018-08-22	DAX	Request for extension of the european patent (deleted)
2018-10-24	A4	Supplementary search report drawn up and despatched	Effective date: 20180924
2018-10-24	RIC1	Information provided on ipc code assigned before grant	Ipc: C07K 16/28 20060101ALN20180918BHEP Ipc: C07K 19/00 20060101ALI20180918BHEP Ipc: A61K 39/00 20060101ALN20180918BHEP Ipc: C12N 5/0783 20100101ALN20180918BHEP Ipc: C07K 16/30 20060101ALN20180918BHEP Ipc: C07K 14/725 20060101ALI20180918BHEP Ipc: C07K 14/705 20060101AFI20180918BHEP
2019-05-31	REG	Reference to a national code	Ref country code: HK Ref legal event code: DE Ref document number: 1252643 Country of ref document: HK
2019-09-03	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: EXAMINATION IS IN PROGRESS
2019-10-09	17Q	First examination report despatched	Effective date: 20190906
2020-04-27	GRAP	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOSNIGR1
2020-04-27	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: GRANT OF PATENT IS INTENDED
2020-05-13	RIC1	Information provided on ipc code assigned before grant	Ipc: C07K 16/28 20060101ALN20200409BHEP Ipc: C07K 14/705 20060101AFI20200409BHEP Ipc: C07K 16/30 20060101ALN20200409BHEP Ipc: C07K 14/725 20060101ALI20200409BHEP Ipc: C12N 5/0783 20100101ALN20200409BHEP Ipc: C07K 19/00 20060101ALI20200409BHEP Ipc: A61K 39/00 20060101ALN20200409BHEP
2020-05-27	INTG	Intention to grant announced	Effective date: 20200428
2020-06-24	RAP1	Party data changed (applicant data changed or rights of an application transferred)	Owner name: TCR2 THERAPEUTICS INC.
2020-06-29	GRAS	Grant fee paid	Free format text: ORIGINAL CODE: EPIDOSNIGR3
2020-07-03	GRAA	(expected) grant	Free format text: ORIGINAL CODE: 0009210
2020-07-03	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE PATENT HAS BEEN GRANTED
2020-08-05	AK	Designated contracting states	Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2020-08-05	REG	Reference to a national code	Ref country code: GB Ref legal event code: FG4D
2020-08-05	RIN1	Information on inventor provided before grant (corrected)	Inventor name: HOFMEISTER, ROBERT Inventor name: BAEUERLE, PATRICK Inventor name: SIECZKIEWICZ, GREGORY
2020-08-14	REG	Reference to a national code	Ref country code: CH Ref legal event code: EP
2020-08-15	REG	Reference to a national code	Ref country code: AT Ref legal event code: REF Ref document number: 1298602 Country of ref document: AT Kind code of ref document: T Effective date: 20200815
2020-08-26	REG	Reference to a national code	Ref country code: NL Ref legal event code: FP
2020-08-27	REG	Reference to a national code	Ref country code: DE Ref legal event code: R096 Ref document number: 602016041479 Country of ref document: DE
2020-09-02	REG	Reference to a national code	Ref country code: IE Ref legal event code: FG4D
2020-09-22	REG	Reference to a national code	Ref country code: PT Ref legal event code: SC4A Ref document number: 3298033 Country of ref document: PT Date of ref document: 20200922 Kind code of ref document: T Free format text: AVAILABILITY OF NATIONAL TRANSLATION Effective date: 20200915
2020-10-05	REG	Reference to a national code	Ref country code: DK Ref legal event code: T3 Effective date: 20200928
2020-10-20	REG	Reference to a national code	Ref country code: SE Ref legal event code: TRGR
2020-11-10	REG	Reference to a national code	Ref country code: FI Ref legal event code: FGE
2020-11-16	REG	Reference to a national code	Ref country code: NO Ref legal event code: T2 Effective date: 20200805
2020-12-14	REG	Reference to a national code	Ref country code: GR Ref legal event code: EP Ref document number: 20200402895 Country of ref document: GR Effective date: 20201116
2020-12-28	REG	Reference to a national code	Ref country code: LT Ref legal event code: MG4D
2021-01-29	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200805 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200805 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201105
2021-02-15	REG	Reference to a national code	Ref country code: CH Ref legal event code: NV Representative=s name: STOLMAR AND PARTNER INTELLECTUAL PROPERTY S.A., CH
2021-02-26	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200805 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200805 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201205
2021-03-29	REG	Reference to a national code	Ref country code: HU Ref legal event code: AG4A Ref document number: E051661 Country of ref document: HU
2021-04-19	REG	Reference to a national code	Ref country code: ES Ref legal event code: FG2A Ref document number: 2819976 Country of ref document: ES Kind code of ref document: T3 Effective date: 20210419
2021-04-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200805 Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200805 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200805 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200805
2021-05-04	REG	Reference to a national code	Ref country code: DE Ref legal event code: R026 Ref document number: 602016041479 Country of ref document: DE
2021-05-11	PLBI	Opposition filed	Free format text: ORIGINAL CODE: 0009260
2021-05-24	PLAX	Notice of opposition and request to file observation + time limit sent	Free format text: ORIGINAL CODE: EPIDOSNOBS2
2021-05-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200805
2021-06-08	REG	Reference to a national code	Ref country code: FI Ref legal event code: MDE Opponent name: JONES DAY
2021-06-09	26	Opposition filed	Opponent name: JONES DAY Effective date: 20210504
2021-06-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200805
2021-08-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200805
2021-10-05	PLBB	Reply of patent proprietor to notice(s) of opposition received	Free format text: ORIGINAL CODE: EPIDOSNOBS3
2022-01-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200805 Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210518
2022-02-15	REG	Reference to a national code	Ref country code: AT Ref legal event code: UEP Ref document number: 1298602 Country of ref document: AT Kind code of ref document: T Effective date: 20200805
2022-10-28	REG	Reference to a national code	Ref country code: HU Ref legal event code: HC9C Owner name: TCR2 THERAPEUTICS INC., US
2023-06-09	PUAH	Patent maintained in amended form	Free format text: ORIGINAL CODE: 0009272
2023-06-09	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: PATENT MAINTAINED AS AMENDED
2023-06-28	P01	Opt-out of the competence of the unified patent court (upc) registered	Effective date: 20230523
2023-06-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200805
2023-07-12	27A	Patent maintained in amended form	Effective date: 20230712
2023-07-12	AK	Designated contracting states	Kind code of ref document: B2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2023-07-12	REG	Reference to a national code	Ref country code: DE Ref legal event code: R102 Ref document number: 602016041479 Country of ref document: DE
2023-09-06	REG	Reference to a national code	Ref country code: NL Ref legal event code: FP
2023-10-02	REG	Reference to a national code	Ref country code: DK Ref legal event code: T4 Effective date: 20230926
2023-10-16	REG	Reference to a national code	Ref country code: NO Ref legal event code: T2 Effective date: 20200805
2023-10-17	REG	Reference to a national code	Ref country code: SE Ref legal event code: RPEO
2023-11-30	REG	Reference to a national code	Ref country code: GR Ref legal event code: EP Ref document number: 20230401766 Country of ref document: GR Effective date: 20231113
2024-02-09	REG	Reference to a national code	Ref country code: HK Ref legal event code: AM43 Ref document number: 1252643 Country of ref document: HK
2024-02-23	REG	Reference to a national code	Ref country code: ES Ref legal event code: DC2A Ref document number: 2819976 Country of ref document: ES Kind code of ref document: T5 Effective date: 20240223
2024-04-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200805
2024-09-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200805
2025-06-17	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: NL Payment date: 20250526 Year of fee payment: 10
2025-07-08	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: FI Payment date: 20250526 Year of fee payment: 10
2025-07-09	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: PL Payment date: 20250505 Year of fee payment: 10 Ref country code: DE Payment date: 20250529 Year of fee payment: 10
2025-07-10	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: GB Payment date: 20250527 Year of fee payment: 10 Ref country code: ES Payment date: 20250602 Year of fee payment: 10 Ref country code: DK Payment date: 20250526 Year of fee payment: 10
2025-07-14	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: HU Payment date: 20250515 Year of fee payment: 10 Ref country code: NO Payment date: 20250530 Year of fee payment: 10
2025-07-15	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: BE Payment date: 20250527 Year of fee payment: 10 Ref country code: IT Payment date: 20250521 Year of fee payment: 10
2025-07-15	REG	Reference to a national code	Ref country code: AT Ref legal event code: UEP Ref document number: 1298602 Country of ref document: AT Kind code of ref document: T Effective date: 20230712
2025-07-17	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: PT Payment date: 20250505 Year of fee payment: 10
2025-07-18	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: FR Payment date: 20250526 Year of fee payment: 10
2025-07-21	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: GR Payment date: 20250528 Year of fee payment: 10
2025-07-23	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: CH Payment date: 20250601 Year of fee payment: 10
2025-07-24	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: AT Payment date: 20250505 Year of fee payment: 10
2025-07-25	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: TR Payment date: 20250515 Year of fee payment: 10
2025-07-29	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: IE Payment date: 20250527 Year of fee payment: 10
2025-07-30	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: SE Payment date: 20250527 Year of fee payment: 10

Publication	Publication Date	Title
GB2564823B (en)	2020-01-29	Compositions and methods for TCR reprogramming using fusion proteins
EP3298033A4 (de)	2018-10-24	Zusammensetzungen und verfahren für tcr-programmierung mit fusionsproteinen
SG11202008721SA (en)	2020-10-29	Compositions and methods for tcr reprogramming using fusion proteins
SG11202100838QA (en)	2021-02-25	Compositions and methods for tcr reprogramming using target specific fusion proteins
EP3244727A4 (de)	2018-10-31	Insektizide proteine und verfahren zu deren verwendung
EP3155018A4 (de)	2018-01-10	Antikörperfusionsproteine mit konstanter region und zusammensetzungen daraus
EP3147298A4 (de)	2017-12-06	Pd-l1-fusionsprotein und verwendung davon
IL251194A0 (en)	2017-05-29	Fusion proteins, recombinant bacteria, and methods for using recombinant bacteria
EP3148573A4 (de)	2017-11-15	Ox40l-fusionsproteine und verwendungen davon
IL250622A0 (en)	2017-04-30	Prepared sirp-alpha fusion proteins and pharmaceutical preparations containing them
CA3268091A1 (en)	2026-03-02	Plant derived insecticidal proteins and methods for their use
EP3019531A4 (de)	2017-03-15	Immunglobulinfusionsproteine und zusammensetzungen davon
CA3290904A1 (en)	2026-03-02	Insecticidal proteins and methods for their use
EP3188758A4 (de)	2017-07-19	Sirp-alpha-antikörperfusionsproteine
EP3324996A4 (de)	2019-04-17	Gdf11-bindende proteine und verwendungen davon
EP3274457A4 (de)	2018-08-08	Follistatin-assoziierte fusionsproteine und verwendungen davon
EP3225690A4 (de)	2018-06-20	Verfahren zur herstellung bakterieller polysaccharidmodifizierter rekombinanter fusionsproteine und verwendung davon
CA3288875A1 (en)	2026-03-02	Multivalent and multispecific dr5-binding fusion proteins
EP3199179A4 (de)	2017-11-29	Formulierung aus rekombinantem fusionsprotein
EP3199555A4 (de)	2017-10-18	Formulierung aus rekombinantem fusionsprotein
EP3256163A4 (de)	2018-10-10	Verfahren und zusammensetzungen zur modulierung von lilr-proteinen
SG11202101811VA (en)	2021-03-30	Compositions and methods for tcr reprogramming using fusion proteins
EP3253797A4 (de)	2018-10-03	Chemokin-immunoglobulin-fusionspolypeptide, zusammensetzungen daraus, verfahren zur herstellung und verwendung davon
IL291236A (en)	2022-05-01	Compositions and methods for reprogramming tcr using fusion proteins
IL297395B1 (en)	2023-09-01	btla fusion protein agonists and uses thereof